{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:44:41Z","timestamp":1781588681680,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Complications due to Staphylococcus aureus infections are a major health concern as current therapies lack broad coverage; therefore, development of a broad neutralizing therapy is critical. We previously showed that a monoclonal antibody combination comprising suvratoxumab and AZD7745, targeting respectively alpha toxin and clumping factor A (ClfA), 2 S aureus virulence factors, provided broad strain coverage in a mouse model. To understand the basis for the broad strain coverage of AZD7745, the epitope was determined. Moreover, we surveyed a global collection of bacteremia isolates to study AZD7745 epitope conservation and neutralizing activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>AZD7745 epitope was determined from the co-crystal structure of AZD7745 Fab with the N2N3 fibrinogen binding domain of ClfA (at 1.58\u2005\u00c5). A geographically diverse collection of 174 S aureus bacteremia isolates was collected between 2022 and 2023. Whole genome sequencing was performed to determine the presence of the clfA gene and AZD7745 epitope conservation. AZD7745 neutralizing activity was tested in vitro against a representative strain of each ClfA variant in a fibrinogen\/ClfA binding assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The AZD7745 epitope contains 12 binding residues on the ClfA N3 domain. Among the 174 isolates, we identified 45 ClfA subtypes with 29 presenting amino acid variations on contact residues. Nonetheless, AZD7745 exhibited neutralizing activity against each subtype. We showed that AZD7745 binding to ClfA N3 domain imposes a conformational change that prevents fibrinogen binding to ClfA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ClfA is ubiquitously present on S aureus global clinical isolates, and AZD7745 epitope is highly conserved. This suggests that AZD7745 can confer broad coverage against S aureus.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf357","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T17:47:12Z","timestamp":1752083232000},"page":"e421-e430","source":"Crossref","is-referenced-by-count":2,"title":["Structure of ClfA002 in Complex With Neutralizing Antibody AZD7745 Provides Insight into Its Broad Neutralization Mechanism in <i>Staphylococcus aureus<\/i> Infection"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-8131","authenticated-orcid":false,"given":"Christine","family":"Tkaczyk","sequence":"first","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-4461","authenticated-orcid":false,"given":"Tal","family":"Keren-Kaplan","sequence":"additional","affiliation":[{"name":"Biologics Engineering, Oncology R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gamson","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-7029","authenticated-orcid":false,"given":"Paul","family":"Warrener","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Semenova","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnita","family":"Barnes","sequence":"additional","affiliation":[{"name":"Biologics Engineering, Oncology R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-0760","authenticated-orcid":false,"given":"Bahar","family":"Ahani","sequence":"additional","affiliation":[{"name":"Bioinformatics, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret R","family":"Sellman","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Podlaha","sequence":"additional","affiliation":[{"name":"Bioinformatics, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-9202","authenticated-orcid":false,"given":"Vaheh","family":"Oganesyan","sequence":"additional","affiliation":[{"name":"Biologics Engineering, Oncology R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2025092306174052500_jiaf357-B1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","article-title":"Staphylococcus aureus infections","volume":"339","author":"Lowy","year":"1998","journal-title":"N Engl J Med"},{"key":"2025092306174052500_jiaf357-B2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijid.2005.07.003","article-title":"Five years of nosocomial gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes","volume":"10","author":"Sligl","year":"2006","journal-title":"Int J Infect Dis"},{"key":"2025092306174052500_jiaf357-B3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"GBD 2019 Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2025092306174052500_jiaf357-B4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mib.2015.07.014","article-title":"Antibacterial monoclonal antibodies: the next generation?","volume":"27","author":"DiGiandomenico","year":"2015","journal-title":"Curr Opin Microbiol"},{"key":"2025092306174052500_jiaf357-B5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s42770-023-01015-0","article-title":"Oral doxycycline to carbapenem-resistant Acinetobacter baumannii infection as a polymyxin-sparing strategy: results from a retrospective cohort","volume":"54","author":"Tuon","year":"2023","journal-title":"Braz J Microbiol"},{"key":"2025092306174052500_jiaf357-B6","doi-asserted-by":"crossref","first-page":"e1002307","DOI":"10.1371\/journal.ppat.1002307","article-title":"Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood","volume":"7","author":"McAdow","year":"2011","journal-title":"PLoS Pathog"},{"key":"2025092306174052500_jiaf357-B7","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/IAI.00562-12","article-title":"Coagulases as determinants of protective immune responses against Staphylococcus aureus","volume":"80","author":"McAdow","year":"2012","journal-title":"Infect Immun"},{"key":"2025092306174052500_jiaf357-B8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1432-1033.1997.00416.x","article-title":"Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen","volume":"247","author":"McDevitt","year":"1997","journal-title":"Eur J Biochem"},{"key":"2025092306174052500_jiaf357-B9","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood-2012-09-453894","article-title":"Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia","volume":"121","author":"Flick","year":"2013","journal-title":"Blood"},{"key":"2025092306174052500_jiaf357-B10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrmicro3161","article-title":"Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus","volume":"12","author":"Foster","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"2025092306174052500_jiaf357-B11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0092-8674(03)00809-2","article-title":"A \u201cdock, lock, and latch\u201d structural model for a staphylococcal adhesin binding to fibrinogen","volume":"115","author":"Ponnuraj","year":"2003","journal-title":"Cell"},{"key":"2025092306174052500_jiaf357-B12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ebiom.2016.09.027","article-title":"Lessons from the crystal structure of the S. aureus surface protein clumping factor A in complex with tefibazumab, an inhibiting monoclonal antibody","volume":"13","author":"Ganesh","year":"2016","journal-title":"EBioMedicine"},{"key":"2025092306174052500_jiaf357-B13","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1073\/pnas.1718104115","article-title":"Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion","volume":"115","author":"Herman-Bausier","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025092306174052500_jiaf357-B14","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1128\/IAI.01065-09","article-title":"Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis","volume":"78","author":"Hair","year":"2010","journal-title":"Infect Immun"},{"key":"2025092306174052500_jiaf357-B15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1086\/588825","article-title":"Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b","volume":"198","author":"Hair","year":"2008","journal-title":"J Infect Dis"},{"key":"2025092306174052500_jiaf357-B16","doi-asserted-by":"crossref","first-page":"e00528-16","DOI":"10.1128\/mBio.00528-16","article-title":"Targeting alpha toxin and ClfA with a multimechanistic monoclonal-antibody\u2013based approach for prophylaxis of serious Staphylococcus aureus disease","volume":"7","author":"Tkaczyk","year":"2016","journal-title":"mBio"},{"key":"2025092306174052500_jiaf357-B17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/AAC.50.2.511-518.2006","article-title":"Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo","volume":"50","author":"Vernachio","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306174052500_jiaf357-B18","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1128\/IAI.71.12.6864-6870.2003","article-title":"Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A","volume":"71","author":"Hall","year":"2003","journal-title":"Infect Immun"},{"key":"2025092306174052500_jiaf357-B19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jpeds.2007.04.060","article-title":"Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants","volume":"151","author":"DeJonge","year":"2007","journal-title":"J Pediatr"},{"key":"2025092306174052500_jiaf357-B20","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00096-06","article-title":"Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia","volume":"50","author":"Weems","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306174052500_jiaf357-B21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/JB.188.2.669-676.2006","article-title":"Microarrays reveal that each of the ten dominant lineages of Staphylococcus aureus has a unique combination of surface-associated and regulatory genes","volume":"188","author":"Lindsay","year":"2006","journal-title":"J Bacteriol"},{"key":"2025092306174052500_jiaf357-B22","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/JCM.42.9.4275-4283.2004","article-title":"Uses of Staphylococcus aureus GeneChips in genotyping and genetic composition analysis","volume":"42","author":"Dunman","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"Suppl","key":"2025092306174052500_jiaf357-B23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/hv.7.0.14562","article-title":"Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity","volume":"7","author":"Murphy","year":"2011","journal-title":"Hum Vaccin"},{"key":"2025092306174052500_jiaf357-B24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-2180-10-173","article-title":"Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions","volume":"10","author":"McCarthy","year":"2010","journal-title":"BMC Microbiol"},{"key":"2025092306174052500_jiaf357-B25","doi-asserted-by":"crossref","first-page":"e00629-17","DOI":"10.1128\/AAC.00629-17","article-title":"Multimechanistic monoclonal antibodies (MAbs) targeting Staphylococcus aureus alpha-toxin and clumping factor A: activity and efficacy comparisons of a MAb combination and an engineered bispecific antibody approach","volume":"61","author":"Tkaczyk","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306174052500_jiaf357-B26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijbiomac.2006.01.012","article-title":"Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins","volume":"39","author":"Tirat","year":"2006","journal-title":"Int J Biol Macromol"},{"key":"2025092306174052500_jiaf357-B27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat Med"},{"key":"2025092306174052500_jiaf357-B28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol"},{"key":"2025092306174052500_jiaf357-B29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2025092306174052500_jiaf357-B30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1107\/S0907444909042589","article-title":"Molecular replacement with MOLREP","volume":"66","author":"Vagin","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2025092306174052500_jiaf357-B31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 2","key":"2025092306174052500_jiaf357-B32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1107\/S0108767390010224","article-title":"Improved methods for building protein models in electron density maps and the location of errors in these models","volume":"47","author":"Jones","year":"1991","journal-title":"Acta Crystallogr A"},{"key":"2025092306174052500_jiaf357-B33","author":"Schr\u00f6dinger"},{"key":"2025092306174052500_jiaf357-B34","author":"Chemical Computing Group."},{"key":"2025092306174052500_jiaf357-B35","doi-asserted-by":"crossref","first-page":"W276","DOI":"10.1093\/nar\/gkac240","article-title":"Search and sequence analysis tools services from EMBL-EBI in 2022","volume":"50","author":"Madeira","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2025092306174052500_jiaf357-B36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-014-0090-6","article-title":"SRST2: rapid genomic surveillance for public health and hospital microbiology labs","volume":"6","author":"Inouye","year":"2014","journal-title":"Genome Med"},{"key":"2025092306174052500_jiaf357-B37","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1093\/emboj\/cdf619","article-title":"A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A","volume":"21","author":"Deivanayagam","year":"2002","journal-title":"EMBO J"},{"key":"2025092306174052500_jiaf357-B38","doi-asserted-by":"crossref","first-page":"e1000226","DOI":"10.1371\/journal.ppat.1000226","article-title":"A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics","volume":"4","author":"Ganesh","year":"2008","journal-title":"PLoS Pathog"},{"key":"2025092306174052500_jiaf357-B39","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1128\/IAI.73.8.5229-5232.2005","article-title":"Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus","volume":"73","author":"Domanski","year":"2005","journal-title":"Infect Immun"},{"key":"2025092306174052500_jiaf357-B40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4161\/hv.34414","article-title":"Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study","volume":"11","author":"Fattom","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2025092306174052500_jiaf357-B41","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2013.3010","article-title":"Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial","volume":"309","author":"Fowler","year":"2013","journal-title":"JAMA"},{"key":"2025092306174052500_jiaf357-B42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-pathol-012615-044351","article-title":"Pathogenesis of Staphylococcus aureus bloodstream infections","volume":"11","author":"Thomer","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"2025092306174052500_jiaf357-B43","doi-asserted-by":"crossref","first-page":"705360","DOI":"10.3389\/fimmu.2021.705360","article-title":"Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies","volume":"12","author":"Clegg","year":"2021","journal-title":"Front Immunol"},{"key":"2025092306174052500_jiaf357-B44","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/toxins5061140","article-title":"Staphylococcus aureus alpha-toxin: nearly a century of intrigue","volume":"5","author":"Berube","year":"2013","journal-title":"Toxins (Basel)"},{"key":"2025092306174052500_jiaf357-B45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.semcdb.2017.04.003","article-title":"Staphylococcus aureus pore-forming toxins: the interface of pathogen and host complexity","volume":"72","author":"Seilie","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"2025092306174052500_jiaf357-B46","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1128\/AAC.00357-16","article-title":"Staphylococcus aureus alpha-toxin is conserved among diverse hospital respiratory isolates collected from a global surveillance study and is neutralized by monoclonal antibody MEDI4893","volume":"60","author":"Tabor","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025092306174052500_jiaf357-B47","doi-asserted-by":"crossref","first-page":"29874","DOI":"10.1074\/jbc.M114.601328","article-title":"Mechanisms of neutralization of a human anti-alpha-toxin antibody","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J Biol Chem"},{"key":"2025092306174052500_jiaf357-B48","first-page":"E5094","article-title":"Mouse model of hematogenous implant-related Staphylococcus aureus biofilm infection reveals therapeutic targets","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025092306174052500_jiaf357-B49","doi-asserted-by":"crossref","first-page":"e0013022","DOI":"10.1128\/msphere.00130-22","article-title":"Neutralizing Staphylococcus aureus virulence with AZD6389, a three mAb combination, accelerates closure of a diabetic polymicrobial wound","volume":"7","author":"Tkaczyk","year":"2022","journal-title":"mSphere"},{"key":"2025092306174052500_jiaf357-B50","doi-asserted-by":"crossref","first-page":"e0183220","DOI":"10.1128\/AAC.01832-20","article-title":"Multimechanistic monoclonal antibody combination targeting key Staphylococcus aureus virulence determinants in a rabbit model of prosthetic joint infection","volume":"65","author":"Mao","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf357\/63713669\/jiaf357.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/e421\/63713669\/jiaf357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/e421\/63713669\/jiaf357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T10:21:09Z","timestamp":1758622869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/3\/e421\/8195836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf357","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,7,9]]}}}